RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases

Reuters10-16

RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases

RetinalGenix Technologies Inc. announced that it has entered into a contract with Seer, Inc., a life sciences company, to collaborate on early detection of neurodegenerative, systemic, and retinal diseases. The agreement involves integrating RetinalGenix's ultra-high-resolution retinal imaging technology with Seer's proteomic profiling platform to identify novel biomarkers for earlier detection and improved monitoring of conditions such as Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases. The collaboration includes research, development, and clinical validation programs aimed at accelerating diagnostic innovation and enabling broader deployment of early-detection solutions in clinical and home-based care settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RetinalGenix Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546622-en) on October 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575166497?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-16 17:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575166497","market":"nz","top_or_hot":-1,"title":"RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RetinalGenix Technologies Inc. announced that it has entered into a contract with <a href=\"https://laohu8.com/S/SEER\">Seer, Inc.</a>, a life sciences company, to collaborate on early detection of neurodegenerative, systemic, and retinal diseases. The agreement involves integrating RetinalGenix's ultra-high-resolution retinal imaging technology with Seer's proteomic profiling platform to identify novel biomarkers for earlier detection and improved monitoring of conditions such as Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases. The collaboration includes research, development, and clinical validation programs aimed at accelerating diagnostic innovation and enabling broader deployment of early-detection solutions in clinical and home-based care settings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RetinalGenix Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546622-en) on October 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-16 17:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RetinalGenix Technologies Inc. announced that it has entered into a contract with <a href=\"https://laohu8.com/S/SEER\">Seer, Inc.</a>, a life sciences company, to collaborate on early detection of neurodegenerative, systemic, and retinal diseases. The agreement involves integrating RetinalGenix's ultra-high-resolution retinal imaging technology with Seer's proteomic profiling platform to identify novel biomarkers for earlier detection and improved monitoring of conditions such as Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases. The collaboration includes research, development, and clinical validation programs aimed at accelerating diagnostic innovation and enabling broader deployment of early-detection solutions in clinical and home-based care settings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RetinalGenix Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546622-en) on October 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL1zfMqD:1","article_id":"2575166497","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575166497","pubTimestamp":1760605280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"RetinalGenix Technologies Inc. announced that it has entered into a contract with Seer, Inc., a life sciences company, to collaborate on early detection of neurodegenerative, systemic, and retinal diseases. The agreement involves integrating RetinalGenix's ultra-high-resolution retinal imaging technology with Seer's proteomic profiling platform to identify novel biomarkers for earlier detection and improved monitoring of conditions such as Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases. The collaboration includes research, development, and clinical validation programs aimed at accelerating diagnostic innovation and enabling broader deployment of early-detection solutions in clinical and home-based care settings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","RTGN":"RetinalGeniX Technologies Inc","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4082":"医疗保健设备","BK4121":"生命科学工具和服务","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SEER":"Seer, Inc."},"translate_title":"RetinalGenix Technologies与Seer Bio签约，推进神经退行性全身性和视网膜疾病的早期检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"RTGN":0.9,"SEER":0.9},"content_text":"RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases\n    \n\n        RetinalGenix Technologies Inc. announced that it has entered into a contract with Seer, Inc., a life sciences company, to collaborate on early detection of neurodegenerative, systemic, and retinal diseases. The agreement involves integrating RetinalGenix's ultra-high-resolution retinal imaging technology with Seer's proteomic profiling platform to identify novel biomarkers for earlier detection and improved monitoring of conditions such as Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases. The collaboration includes research, development, and clinical validation programs aimed at accelerating diagnostic innovation and enabling broader deployment of early-detection solutions in clinical and home-based care settings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RetinalGenix Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546622-en) on October 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575166497","isCrawlerRequest":true}